Contact Us

Contact us with any questions or comments regarding our novel approach to treating infectious, inflammatory, and degenerative diseases with our plasma gelsolin technology platform.

Name

Phone

Organization

Role

Scientist/Academic Media Investor Other

Message

Stay informed of our latest discoveries and news.

GENERAL NEWS/MEDIA

September 2020: BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia

September 4, 2020

August 2020: Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity

August 17, 2020

August 2020: BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment

August 6, 2020

July 2020: BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment

July 22, 2020

WIB-Metro New York: Biotech Leadership in the time of COVID-19: Impact, Opportunity, and Resilience

August 20, 2020

BioNJ COVID-19 Rapid Fire Research Showcase

June 5, 2020

Tweets by BioAegis

COMPANY DETAILS

LOCATION:
BioAegis Therapeutics
North Brunswick, NJ

MEDIA INQUIRIES:
Contact: Christine Lagana
clagana@bioaegistx.com

INVESTOR INQUIRIES:
Contact: Steven Cordovano
scordovano@bioaegistx.com

JOIN OUR TEAM

Facebook

Twitter

Youtube

Our COVID19 phase 2 clinical trial for our lead product, rhu-pGSN, has begun.

Contact Us

Stay informed of our latest discoveries and news.

COMPANY DETAILS

FOLLOW US